Tarsus Pharmaceuticals Inc (NASDAQ: TARS) on Friday, soared 10.89% from the previous trading day, before settling in for the closing price of $58.77. Within the past 52 weeks, TARS’s price has moved between $31.99 and $59.78.
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -66.60%. The company achieved an average annual earnings per share of 53.54%. With a float of $38.61 million, this company’s outstanding shares have now reached $42.21 million.
Tarsus Pharmaceuticals Inc (TARS) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Tarsus Pharmaceuticals Inc is 8.53%, while institutional ownership is 107.61%. The most recent insider transaction that took place on Sep 24 ’25, was worth 332,220. In this transaction President/CEO and Board Chair of this company sold 6,000 shares at a rate of $55.37, taking the stock ownership to the 812,106 shares. Before that another transaction happened on Sep 24 ’25, when Company’s Officer proposed sale 6,000 for $55.37, making the entire transaction worth $332,208.
Tarsus Pharmaceuticals Inc (TARS) Recent Fiscal highlights
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.61 earnings per share (EPS) for the period topping the consensus outlook (set at -1) by 0.39. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.03 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 53.54% per share during the next fiscal year.
Tarsus Pharmaceuticals Inc (NASDAQ: TARS) Trading Performance Indicators
Tarsus Pharmaceuticals Inc (TARS) is currently performing well based on its current performance indicators. A quick ratio of 5.21 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.31.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.33, a number that is poised to hit -0.36 in the next quarter and is forecasted to reach 0.97 in one year’s time.
Technical Analysis of Tarsus Pharmaceuticals Inc (TARS)
Compared to the last year’s volume of 0.67 million, its volume of 0.7 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 78.35%.
During the past 100 days, Tarsus Pharmaceuticals Inc’s (TARS) raw stochastic average was set at 97.09%, which indicates a significant increase from 95.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 2.57 in the past 14 days, which was higher than the 1.94 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $52.64, while its 200-day Moving Average is $48.39. Nevertheless, the first resistance level for the watch stands at $67.77 in the near term. At $70.36, the stock is likely to face the second major resistance level. The third major resistance level sits at $74.76. If the price goes on to break the first support level at $60.78, it is likely to go to the next support level at $56.38. Now, if the price goes above the second support level, the third support stands at $53.79.
Tarsus Pharmaceuticals Inc (NASDAQ: TARS) Key Stats
Market capitalization of the company is 2.75 billion based on 42,214K outstanding shares. Right now, sales total 182,950 K and income totals -115,550 K. The company made 102,660 K in profit during its latest quarter, and -20,340 K in sales during its previous quarter.
